Recombinant Rana arvalis Ranatuerin-2AVb

What is the structure and sequence of Ranatuerin-2AVb?

Ranatuerin-2AVb is a 28-amino acid peptide with the sequence GLMDMVKGAAKNLFASALDTLKCKITGC. In three-letter code, this translates to Gly-Leu-Met-Asp-Met-Val-Lys-Gly-Ala-Ala-Lys-Asn-Leu-Phe-Ala-Ser-Ala-Leu-Asp-Thr-Leu-Lys-Cys-Lys-Ile-Thr-Gly-Cys . The peptide contains a disulfide bridge formed between the two cysteine residues at positions 23 and 28, creating what is known as the "Rana box" at the C-terminus. This structural feature is characteristic of many ranatuerin peptides isolated from amphibian skin secretions .

Structurally, Ranatuerin-2AVb adopts an α-helical conformation in membrane-mimetic environments, which is critical for its antimicrobial activity. Secondary structure analysis using circular dichroism (CD) spectroscopy typically shows characteristic minima at 208 and 222 nm when the peptide is in a helical conformation, particularly in the presence of trifluoroethanol (TFE) .

What expression systems are used for producing recombinant Ranatuerin-2AVb?

Multiple expression systems have been successfully employed for the recombinant production of Ranatuerin-2AVb, each offering distinct advantages depending on research requirements:

• Baculovirus expression system: This insect cell-based system is suitable for producing Ranatuerin-2AVb with proper folding and disulfide bond formation. The recombinant protein expressed using this system typically achieves purity levels of >85% as determined by SDS-PAGE .

• Mammalian cell expression system: Mammalian cells provide a eukaryotic environment that can facilitate proper post-translational modifications and folding. Products generated using this system also achieve purity levels of >85% as assessed by SDS-PAGE .

When selecting an expression system, researchers should consider factors such as required yield, post-translational modifications, and downstream applications. For structural studies requiring highly pure protein, additional purification steps beyond the manufacturer's processing may be necessary.

How should Ranatuerin-2AVb be stored and reconstituted for experimental use?

Proper storage and reconstitution of Ranatuerin-2AVb are critical for maintaining its biological activity. The following protocol is recommended based on established guidelines:

Storage:

• Store lyophilized peptide at -20°C for up to 12 months .

• For extended storage, maintain at -80°C .

• Avoid repeated freeze-thaw cycles, which can lead to degradation and loss of activity .

Reconstitution:

• Briefly centrifuge the vial prior to opening to bring contents to the bottom .

• Reconstitute in deionized sterile water to a concentration of 0.1-1.0 mg/mL .

• For long-term storage of reconstituted peptide, add glycerol to a final concentration of 5-50% (50% is typically recommended) .

• Aliquot the reconstituted peptide to minimize freeze-thaw cycles .

• Working aliquots can be stored at 4°C for up to one week .

The shelf life of reconstituted Ranatuerin-2AVb varies depending on the formulation:

• Liquid form: approximately 6 months at -20°C/-80°C .

• Lyophilized form: approximately 12 months at -20°C/-80°C .

What is the Rana box, and what role does it play in Ranatuerin-2AVb's function?

The Rana box is a structural motif found in many antimicrobial peptides isolated from amphibian skin, including Ranatuerin-2AVb. It consists of a cyclic heptapeptide domain formed by a disulfide bridge between two cysteine residues near the C-terminus of the peptide .

In Ranatuerin-2AVb, the Rana box is formed by the sequence portion LKCKITGC, with the disulfide bridge connecting the cysteine residues .

The functional significance of the Rana box has been investigated in related ranatuerin peptides, with interesting findings:

• In some ranatuerin peptides like R2AW from Amolops wuyiensis, studies have shown that serine-substitution of the cysteine residues and even complete removal of the cyclic domain resulted in peptides with similar antibacterial activity to the native peptide .

• This suggests that, contrary to previous assumptions, the disulfide bridge and Rana box may be dispensable for the antibacterial activity of certain ranatuerin-2 peptides .

What are the recommended methods for assessing Ranatuerin-2AVb purity?

Accurate assessment of Ranatuerin-2AVb purity is essential for ensuring experimental reproducibility. The following analytical methods are recommended:

• SDS-PAGE (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis):

  • Standard method for assessing purity based on molecular weight separation.

  • Commercial recombinant preparations typically achieve >85% purity as determined by SDS-PAGE .

  • For visualization, Coomassie blue staining is commonly used, though silver staining offers greater sensitivity for detecting minor impurities.

• HPLC (High-Performance Liquid Chromatography):

  • Reversed-phase HPLC is the gold standard for peptide purity assessment.

  • Synthetic Ranatuerin-2AVb preparations typically achieve >95% purity by HPLC analysis .

  • Higher purity levels (98-99%) can be requested for specialized applications .

• Mass Spectrometry:

  • MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization-Time of Flight) or ESI-MS (Electrospray Ionization Mass Spectrometry) provide precise molecular weight confirmation.

  • These methods can detect chemical modifications, truncations, or synthesis byproducts.

When reporting experimental results, researchers should specify both the purity level and the analytical method used for its determination, as different techniques have varying sensitivities and limitations.

How does the disulfide bridge in Ranatuerin-2AVb affect its antibacterial activity?

Research on ranatuerin-2-AW (R2AW) from Amolops wuyiensis has provided valuable insights that may be applicable to Ranatuerin-2AVb. In these studies:

• Linear analogs were created by substituting the cysteine residues with serine (which has similar chemical properties but cannot form disulfide bonds) .

• The serine-substituted peptides showed similar antibacterial activity to the native peptide, suggesting that the disulfide bridge is not essential for antimicrobial function .

• Furthermore, truncated analogs with complete removal of the cyclic domain also maintained comparable antibacterial activity .

These findings suggest that the antibacterial mechanism of ranatuerin peptides may be primarily dependent on their ability to adopt amphipathic helical structures rather than on the presence of the disulfide bridge. The α-helical conformation allows the peptide to interact with bacterial membranes, with positively charged residues interacting with negatively charged bacterial membrane components and hydrophobic residues inserting into the lipid bilayer .

For researchers working with Ranatuerin-2AVb, these insights suggest that:

• Experimental designs should consider testing both the cyclic (native) form and linear analogs to determine if similar structure-activity relationships apply.

• Circular dichroism (CD) spectroscopy should be employed to compare the secondary structure of cyclic and linear forms in membrane-mimetic environments.

• Functional assays should assess not only antibacterial activity but also membrane permeabilization capacity to determine if the mechanism of action is altered by the absence of the disulfide bridge.

What methodologies are most effective for studying Ranatuerin-2AVb's mechanism of action against bacterial membranes?

Investigating Ranatuerin-2AVb's mechanism of action against bacterial membranes requires a multi-faceted experimental approach combining both biophysical and microbiological techniques:

• Membrane Permeabilization Assays:

  • Fluorescent dye leakage assays using calcein or propidium iodide to quantify membrane disruption.

  • SYTOX Green uptake assay to measure the ability of Ranatuerin-2AVb to compromise bacterial membrane integrity.

  • Measurement of transmembrane potential using DiSC3(5) (3,3′-dipropylthiadicarbocyanine iodide) to detect membrane depolarization.

• Biophysical Interaction Studies:

  • Surface plasmon resonance (SPR) to determine binding kinetics to model membranes.

  • Isothermal titration calorimetry (ITC) to measure thermodynamic parameters of peptide-membrane interactions.

  • Langmuir monolayer studies to assess peptide insertion into lipid films.

• Microscopy Techniques:

  • Atomic force microscopy (AFM) to visualize membrane disruption at the nanoscale.

  • Transmission electron microscopy (TEM) to observe ultrastructural changes in bacterial cells following treatment.

  • Confocal microscopy with fluorescently labeled peptides to track localization.

• Killing Kinetics Analysis:

  • Time-kill assays to determine the speed of bacterial killing, which can distinguish between membrane-active peptides and those with intracellular targets.

  • Studies with ranatuerin peptides have shown that membrane-disrupting variants can kill bacteria at a highly efficient rate .

• Resistance Development Assessment:

  • Serial passage experiments to evaluate the potential for resistance development.

  • Combination studies with conventional antibiotics to identify synergistic effects.

These methodologies should be applied with appropriate controls, including known membrane-active peptides like melittin and non-membrane-active antimicrobial agents. The bacterial strains selected should include both Gram-positive and Gram-negative species to account for differences in membrane composition and architecture.

How can Ranatuerin-2AVb be modified to enhance its antimicrobial properties while reducing cytotoxicity?

Strategic modifications of Ranatuerin-2AVb can significantly enhance its therapeutic potential by improving antimicrobial efficacy while minimizing toxicity to host cells. Based on studies with related ranatuerin peptides, several effective modification strategies have been identified:

When designing modified Ranatuerin-2AVb variants, researchers should systematically evaluate both antimicrobial activity and cytotoxicity to identify the optimal balance. Minimum inhibitory concentration (MIC) assays against relevant bacterial pathogens, hemolysis assays using human erythrocytes, and cytotoxicity assessments using mammalian cell lines are essential components of this evaluation process.

What in vivo models are appropriate for evaluating Ranatuerin-2AVb's efficacy against resistant bacterial infections?

Selecting appropriate in vivo models is crucial for translating the promising in vitro activity of Ranatuerin-2AVb to potential clinical applications, particularly against resistant bacterial infections. Based on successful approaches with related antimicrobial peptides, the following models are recommended:

• Invertebrate Models:

  • Galleria mellonella (waxworm) infection model: This has been successfully used to evaluate the efficacy of modified ranatuerin peptides against methicillin-resistant Staphylococcus aureus (MRSA) .

  • Advantages include ethical considerations, cost-effectiveness, ability to maintain at room temperature, and presence of an innate immune system with similarities to mammals.

  • The model allows for rapid screening of multiple peptide variants before advancing to mammalian models.

• Mammalian Models:

  • Murine cutaneous infection models: Appropriate for evaluating topical applications of Ranatuerin-2AVb.

  • Murine systemic infection models: Can assess efficacy against bacteremia and disseminated infections.

  • Specialized models based on the target infection:

    • Pulmonary infection models for respiratory pathogens

    • Urinary tract infection models for uropathogens

    • Wound infection models for skin and soft tissue infections

    • Biofilm infection models (e.g., implant-associated infections)

• Ex Vivo Models:

  • Human skin explant models for dermatological applications.

  • Tissue barrier models to assess peptide penetration and activity in different anatomical contexts.

When designing in vivo experiments, several methodological considerations are critical:

• Dose optimization: Determine effective concentrations that balance antimicrobial activity with potential toxicity.

• Formulation development: Identify appropriate vehicles or delivery systems that protect the peptide from degradation and enhance its activity at the infection site.

• Comparative studies: Include conventional antibiotics as comparators, as well as combination treatments to identify potential synergistic effects.

• Timing of intervention: Establish both prophylactic and treatment protocols to determine the optimal therapeutic window.

• Comprehensive endpoints: Measure not only microbial burden but also inflammatory markers, tissue damage, and long-term outcomes.

The promising in vivo efficacy demonstrated by optimized ranatuerin variants in models of MRSA infection suggests that properly designed Ranatuerin-2AVb derivatives may hold significant potential for treating resistant bacterial infections .

What structural analyses should be performed to understand Ranatuerin-2AVb's dual antibacterial and anticancer activities?

Ranatuerin-2AVb and related peptides have demonstrated potential dual antibacterial and anticancer activities . Understanding the structural basis for this dual functionality requires comprehensive structural analyses using complementary techniques:

• High-Resolution Structural Determination:

  • Solution NMR spectroscopy in membrane-mimetic environments (micelles, bicelles) to determine three-dimensional structure.

  • X-ray crystallography of the peptide in complex with model membranes or potential protein targets.

  • Cryo-electron microscopy to visualize peptide-membrane interactions.

• Secondary Structure Analysis:

  • Circular dichroism (CD) spectroscopy under various conditions to assess conformational transitions:

    • In aqueous solution vs. membrane-mimetic environments

    • At different pH values and ionic strengths

    • In the presence of cancer cell membrane extracts vs. bacterial membrane components

  • Fourier transform infrared (FTIR) spectroscopy to complement CD data, particularly for β-sheet content determination.

• Molecular Dynamics Simulations:

  • All-atom simulations of peptide interactions with model bacterial and cancer cell membranes.

  • Free energy calculations to determine preferential binding to different membrane compositions.

  • Identification of key residues involved in membrane interaction through in silico alanine scanning.

• Structure-Activity Relationship Studies:

  • Systematic creation of analogs with modifications at specific positions to identify residues critical for each activity.

  • Comparative analysis of the relationship between structural parameters (hydrophobicity, amphipathicity, helicity) and dual functionality.

  • Evaluation of the effect of stereochemical modifications (D-amino acid substitutions) on specificity.

• Mechanistic Studies:

  • Assessment of membrane permeabilization vs. internalization in bacterial and cancer cells.

  • Identification of potential intracellular targets in cancer cells through pull-down assays and proteomic approaches.

  • Apoptosis vs. necrosis determination in cancer cells to elucidate cell death pathways.

• Biophysical Interaction Studies:

  • Surface plasmon resonance (SPR) to compare binding kinetics to model membranes representing bacterial and cancer cells.

  • Isothermal titration calorimetry (ITC) to measure thermodynamic parameters of these interactions.

  • Fluorescence spectroscopy with environment-sensitive probes to monitor conformational changes upon binding.

Understanding the structural basis for dual functionality could lead to rational design of optimized analogs with enhanced selectivity for either bacterial or cancer cells, or improved dual activity, depending on the therapeutic goal.